Reimbursement and Payer Management of Immune Checkpoint Inhibitors

This market analysis covers price-volume and expenditure ceilings are frequently used across Europe, payers are concerned about the budget impact of immunotherapies,  price reductions are frequently required following label expansions into new populations, immunotherapy drugs present an opportunity for contracting, but payers await more competition and combination therapies pose challenges for payers as many markets do not have a clear path for HTA and price negotiation.